[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Naganobu K, Ogawa H, Uchida K, Yamaguchi R, Ohashi F, Kubo K, Aoki M, Kuwamura M, Ogawa Y, Matsuyama K: Mast cell tumor in the nasal cavity of a dog. J Vet Med Sci; 2000 Sep;62(9):1009-11
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell tumor in the nasal cavity of a dog.
  • An 11-year-old male Shetland sheepdog displayed epistaxis and nasal discharge from the left nasal foramen.
  • Cytological examination of a smear sample obtained by rhinotomy revealed neoplastic mast cells in the nasal cavity, a definitive diagnostic sign of mast cell tumor.
  • The case was treated by surgery combined with radiotherapy and chemotherapy.
  • Eighteen days after the last treatment, marked enlargement of the mandibular lymph nodes and facial edema developed, and the dog was euthanized at the owner's request.
  • At necropsy, metastatic proliferation of mast cells was confirmed in the lymph nodes and liver, but no neoplastic mast cells were observed in the nasal cavity.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11039600.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


2. Kane SV, Karpate AA, Bal M, Juvekar SL, Pai PS: Chemotherapy-induced neuronal maturation in sinonasal teratocarcinosarcoma--a unique observation. Head Neck Pathol; 2009 Mar;3(1):31-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced neuronal maturation in sinonasal teratocarcinosarcoma--a unique observation.
  • Sinonasal teratocarcinosarcoma (SNTCS) is a rare and highly malignant tumour with combined features of a teratoma and carcinosarcoma.
  • We report the first case of a SNTCS in 23 year old male treated with neo-adjuvant chemotherapy followed by cranio-facial resection.
  • The patient presented with a short history of nasal obstruction, epistaxis and headache.
  • On imaging, a bone destroying lesion of left paranasal sinuses and nasal cavity was identified.
  • The diagnosis of SNTCS could be offered only on the third biopsy which showed heterogeneous admixture of primitive neuroectodermal, epithelial and mesenchymal elements.
  • An adequate sampling with high index of suspicion is needed to catch hold this rare tumor.
  • Tumor was excised after 4 cycles of neo-adjuvant chemotherapy.
  • The undifferentiated neuroectodermal cells were completely absent in the post chemotherapy specimen.
  • This case throws light on the morphologic evidence of chemotherapy induced maturation in the neuroectodermal component within SNTCS, an event hitherto not reported in the literature in case of SNTCS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / pathology. Cell Differentiation / drug effects. Neurons / pathology. Nose Neoplasms / pathology. Teratocarcinoma / pathology
  • [MeSH-minor] Biomarkers, Tumor. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Humans. Immunohistochemistry. Male. Neoadjuvant Therapy. Neoplasm Staging. Otorhinolaryngologic Surgical Procedures. Radiotherapy. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1988;45(3):148-52 [3368191.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Mar;112(3):496-500 [7870460.001]
  • [Cites] Hum Pathol. 1998 Jul;29(7):718-22 [9670829.001]
  • [Cites] Ann Diagn Pathol. 2006 Dec;10(6):339-42 [17126251.001]
  • [Cites] Ann Diagn Pathol. 2008 Dec;12(6):415-25 [18995206.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2002 Feb 1;62(2):159-64 [11788149.001]
  • [Cites] Pathology. 1983 Oct;15(4):413-9 [6674870.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):687-91 [15390296.001]
  • [Cites] Cancer. 1968 Apr;21(4):714-21 [5651269.001]
  • [Cites] Cancer. 1976 Aug;38(2):818-23 [974998.001]
  • [Cites] J Surg Oncol. 1977;9(1):21-8 [839794.001]
  • [Cites] Cancer. 1984 May 15;53(10):2140-54 [6322958.001]
  • [Cites] Pathol Int. 2001 Dec;51(12):942-7 [11844067.001]
  • (PMID = 20596986.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2807528
  • [Keywords] NOTNLM ; Neo-adjuvant chemotherapy / Neuronal maturation / Sinonasal tumours / Teratocarcinosarcoma
  •  go-up   go-down


3. Lin CY, Yang SW, Lai CH: Primary malignant melanoma of the nasal cavity. Chang Gung Med J; 2003 Nov;26(11):857-62
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the nasal cavity.
  • Malignant melanoma is a highly lethal melanocytic neoplasm, usually affecting the skin.
  • Primary malignant melanoma of the nasal cavity is rarely seen.
  • Clinically, most patients display initial nonspecific symptoms of unilateral nasal obstruction or epistaxis.
  • The prognosis is generally poor, with a mean survival time of 3.5 years.
  • The usual treatment of choice is radical excision.
  • Radiotherapy and chemotherapy appear to have little effect.
  • We report a fatal case of intranasal cavity malignant melanoma in which the patient initially presented with blood-tinged sputum, productive cough, and intermittent fever.
  • Palliative surgery was performed to excise the nasal cavity tumor.
  • Then, 6 courses of chemotherapy were further administered.
  • Unfortunately, regional cervical nodal involvement and pancreatic head metastases occurred 1.5 years after the diagnosis.
  • We have chosen to discuss this aggressive condition because of its rarity and also to emphasize the importance of its early detection through vigilant attention to nonspecific nasal symptoms.
  • [MeSH-major] Melanoma / pathology. Nasal Cavity. Nose Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14765758.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


Advertisement
4. Megat Shiraz MA, Jong YH, Primuharsa Putra SH: Extramedullary plasmacytoma in the maxillary sinus. Singapore Med J; 2008 Nov;49(11):e310-1
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extramedullary plasmacytoma is a rare malignant plasma cell tumour.
  • Magnetic resonance imaging revealed a right maxillary tumour with extension to the ipsilateral nasal cavity, nasopharynx, right sphenoid and ethmoidal sinuses.
  • He was planned for four cycles of chemotherapy.
  • Unfortunately, in view of the advanced stage of disease, he succumbed to his disease during the first cycle of chemotherapy.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Maxillary Sinus Neoplasms / diagnosis. Maxillary Sinus Neoplasms / radiography
  • [MeSH-minor] Anemia / complications. Antineoplastic Agents / therapeutic use. Fatal Outcome. Humans. Magnetic Resonance Imaging / methods. Male. Maxillary Sinus / pathology. Maxillary Sinus / radiography. Middle Aged. Nasopharynx / pathology. Neoplasm Metastasis. Plasmacytoma / diagnosis. Plasmacytoma / pathology. Plasmacytoma / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037537.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Mattavelli F, Pizzi N, Pennacchioli E, Radaelli S, Calarco G, Quattrone P, Patelli L, Spinelli P: Esthesioneuroblastoma metastatic to the trachea. Acta Otorhinolaryngol Ital; 2009 Jun;29(3):164-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esthesioneuroblastoma is a rare tumour, for which a multimodal approach, including a combination of surgery and radiation, appears to provide the best disease-free and overall survival.
  • The case is reported here of a patient who developed metastatic esthesioneuroblastoma to the trachea 18 months after primary surgery and radiation therapy.
  • The patient was treated by two subsequent N-YAG laser endoscopic resections and chemotherapy.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / secondary. Nasal Cavity. Nose Neoplasms / pathology. Tracheal Neoplasms / secondary

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Treat Options Oncol. 2005 Nov;6(6):509-18 [16242055.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1749-54 [17003718.001]
  • [Cites] Acta Neurochir (Wien). 2005 Jun;147(6):595-601; discussion 601-2 [15806328.001]
  • [Cites] Head Neck. 2005 Mar;27(3):224-31 [15627260.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1964 Sep;73:569-82 [14215937.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1954 Jul 14;29(14):403-5 [13185995.001]
  • [Cites] Respir Med. 1998 Mar;92(3):599-600 [9692131.001]
  • [Cites] J Surg Oncol. 1996 Aug;62(4):249-52 [8691837.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Sep;106(3):537-42 [8361198.001]
  • [Cites] Neurosurgery. 1993 May;32(5):706-14; discussion 714-5 [8492845.001]
  • [Cites] Head Neck Surg. 1987 Nov-Dec;10(2):102-6 [3507417.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1982 Nov-Dec;91(6 Pt 1):648-51 [6184006.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1971 Apr;80(2):192-206 [4323842.001]
  • [Cites] Laryngoscope. 2003 Dec;113(12):2086-90 [14660907.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1186-92 [14623748.001]
  • [Cites] Laryngoscope. 2003 Nov;113(11):1935-8 [14603051.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):112-8 [14515089.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2003 May;260(5):244-7 [12750912.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):276-80 [17372086.001]
  • [Cites] Lung Cancer. 2000 May;28(2):163-70 [10717334.001]
  • [Cites] Head Neck. 2001 Sep;23(9):749-57 [11505485.001]
  • (PMID = 20140164.001).
  • [ISSN] 1827-675X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2815355
  • [Keywords] NOTNLM ; Esthesioneuroblastoma / Malignant tumours / Trachea / Tracheal metastasis
  •  go-up   go-down


6. Díaz Molina JP, Rodrigo Tapia JP, Llorente Pendas JL, Suárez Nieto C: [Sinonasal mucosal melanomas. Review of 17 case]. Acta Otorrinolaringol Esp; 2008 Dec;59(10):489-93
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Melanomas mucosos rinosinusales. Revisión de 17 casos.
  • INTRODUCTION: Mucosal melanomas (MM) represent 1.3 % of all melanomas; 55 % of them are located in the head and neck region mainly in the sinonasal and oropharyngeal cavity.
  • The patients were studied by age, gender, site of presentation of the tumour, symptoms, radiology findings, treatment and course.
  • Twelve cases developed in the nasal cavity and 5 in the paranasal sinuses.
  • Three patients rejected any treatment, 12 of the patients were treated surgically, one received chemotherapy and another chemotherapy plus radiotherapy.
  • The treatment of choice is still surgical resection with wide surgical margins.
  • Even so, the main cause of treatment failure is local recurrence, followed by the development of metastases.
  • Because of the poor prognosis with this tumour, new treatment strategies are necessary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080785.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Gale N, Zidar N, Podboj J, Volavsek M, Luzar B: Inflammatory myofibroblastic tumour of paranasal sinuses with fatal outcome: reactive lesion or tumour? J Clin Pathol; 2003 Sep;56(9):715-7
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumour of paranasal sinuses with fatal outcome: reactive lesion or tumour?
  • Computed tomography scan and magnetic resonance imaging showed an expansive process in the paranasal sinuses, extending into the nasal cavity, orbita, and endocranium.
  • The tumour progressed despite several surgical procedures.
  • Radiotherapy, corticosteroids, and chemotherapy were unsuccessful, and the patient died four years after diagnosis, as a result of extensive intracranial spread of the tumour.
  • It shows that the aggressive behaviour of IMTs is not limited to abdominal and mediastinal locations, and supports recent observations that at least a subset of IMTs represents true neoplasia rather than reactive myofibroblastic proliferation.
  • [MeSH-major] Neoplasms, Muscle Tissue / pathology. Paranasal Sinus Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Epistaxis / etiology. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Pregnancy. Tomography, X-Ray Computed. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2000 Nov;192(3):277-9 [11054708.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):377-84 [10934142.001]
  • [Cites] J Laryngol Otol. 2001 Jul;115(7):563-6 [11485590.001]
  • [Cites] J Laryngol Otol. 2001 Oct;115(10):856-8 [11668009.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Feb;69(2):191-8 [2406675.001]
  • [Cites] Am J Surg Pathol. 1991 Dec;15(12):1146-56 [1746682.001]
  • [Cites] Am J Surg Pathol. 1994 Feb;18(2):148-57 [8291653.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Apr;104(4 Pt 1):329-31 [7717628.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):859-72 [7611533.001]
  • [Cites] J Clin Pathol. 1996 Feb;49(2):164-7 [8655685.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):364-8 [9578087.001]
  • [Cites] Semin Diagn Pathol. 1998 May;15(2):85-101 [9606801.001]
  • [Cites] Semin Diagn Pathol. 1998 May;15(2):102-10 [9606802.001]
  • [Cites] Semin Diagn Pathol. 1998 May;15(2):155-60 [9606806.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):279-86 [10102613.001]
  • [Cites] Lab Invest. 2000 Jul;80(7):1121-6 [10908158.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):569-76 [11406658.001]
  • (PMID = 12944561.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770050
  •  go-up   go-down


8. Ng W, Jacob S, Delaney G, Barton M: Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care. Eur J Cancer; 2009 Aug;45(12):2150-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care.
  • BACKGROUND: We estimated the optimal chemotherapy utilisation rate for head and neck cancer as a benchmark for measuring and improving the quality of cancer care.
  • METHODS: An optimal chemotherapy utilisation tree was constructed using indications for chemotherapy that were identified from evidence-based treatment guidelines.
  • Data on the proportion of patient and tumour-related attributes for which chemotherapy was indicated were obtained and merged with the treatment indications to calculate the optimal utilisation rate.
  • The optimal chemotherapy utilisation rate was compared with actual utilisation rates reported.
  • RESULTS: Chemotherapy is indicated at least once in 36% (95% CI, 33-38%) of all patients with head and neck carcinoma.
  • The optimal utilisation rates by subsites were as follows: lip, 8%; oral cavity, 40%; nasopharynx, 69%; oropharynx, 66%; hypopharynx, 74%; larynx, 43%; salivary gland, 48% and paranasal sinus with nasal cavity, 38%.
  • CONCLUSIONS: The optimal proportion of patients who should receive chemotherapy in the head and neck carcinoma population has risen significantly over the past 20 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19285857.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


9. Slavícek A, Astl J, Válková D, Betka J, Petruzelka L: [Malignant mucosal melanoma of the head and neck]. Sb Lek; 2000;101(4):315-23
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most common site of the tumor are the nasal cavity and paranasal sinuses but melanoma of the oral cavity are described too.
  • Therapy usually consists of surgical resection with or without postoperative radiotherapy and immunochemotherapy eventually.
  • The definite role of a kind of therapy in the treatment of mucosal melanoma is not remains to be defined as the small number of cases make prospective study challenging.
  • Analysis of the metastatic disease, type of therapy and follow-up was retrospectively reviewed.
  • The site of the tumor was the lateral wall of the nasal cavity (five cases), nasal septum (four cases), maxilar cavity (two cases), and ethmoidal cavity, orbitoethmoidal complex, nasopharynx, saccus lacrimalis to ethmoidal sinuses diffused, tonsilla (one case each) and hypopharynx (two cases).
  • Primary treatment was surgical resection in ten cases, in one case with radiation therapy, and in seven cases chemotherapy.
  • In three cases were diagnostic surgery only and one patient was without therapy.
  • Four patients were treated radiation therapy and three chemotherapy after surgery.
  • For nine cases of recurrence of the disease were surgery (in five cases) and chemotherapy (in four cases).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11702570.001).
  • [ISSN] 0036-5327
  • [Journal-full-title] Sborník lékar̆ský
  • [ISO-abbreviation] Sb Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


10. Chami R, Aleynikova O, Abela A, Blais M, Oligny L, Bouron-Dal Soglio D, Patey N: [Juvenile xanthogranuloma of the nasal cavity]. Ann Pathol; 2010 Oct;30(5):374-7
MedlinePlus Health Information. consumer health - Nose Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Juvenile xanthogranuloma of the nasal cavity].
  • [Transliterated title] Xanthogranulome juvénile de la cavité nasale.
  • It is the most frequent type of non-langerhans histiocytosis with a median age of 2 years.
  • The skin lesions tend to regress slowly with time.
  • When the lesions are numerous, they may persist, hence the need for treatment with corticosteroids or chemotherapy.
  • We report an 8-year old girl with JXG of early type without multinucleated and foamy cells.
  • This case presented as a tumour in the inferior meatus of nasal cavity, clinically simulating a rhabdomyosarcoma.
  • This atypical clinical and histological presentation with benign evolution should be recognized since it requires only local treatment.
  • [MeSH-major] Nasal Cavity. Nose Diseases / pathology. Xanthogranuloma, Juvenile / pathology


11. Daele JJ, Vander Poorten V, Rombaux P, Hamoir M: Cancer of the nasal vestibule, nasal cavity and paranasal sinuses. B-ENT; 2005;Suppl 1:87-94; quiz 95-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the nasal vestibule, nasal cavity and paranasal sinuses.
  • The usual clinical presentation of sinonasal tumours includes symptoms that are indistinguishable from inflammatory sinus disease, namely nasal airway obstruction, pain, and epistaxis.
  • Abnormal V1 and/or V2 sensations are a strong indication of the possibility of tumour.
  • Computed tomography is the most reliable and informative imaging tool for evaluating the cancers of the paranasal sinuses.
  • Magnetic resonance imaging is essential for tumour mapping because of the excellent tissue characterisation and the possibility of differentiating between neoplasms and retained secretions.
  • The response of sinonasal tract tumours to radiation therapy varies with the stage and histology of the tumour.
  • Patients with tumour involvement of the skull base, either in the infratemporal fossa or at the fovea ethmoidalis and cribriform plate, should be considered for craniofacial resection.
  • Management of these tumours requires a multimodal approach, involving surgery, radiation therapy and, increasingly in recent years, chemotherapy.
  • [MeSH-major] Nasal Cavity / pathology. Nose Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363270.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 49
  •  go-up   go-down


12. Li TX, Zhao M, Jin GP, Yu SG: [Analysis of 19 cases adenoid cystic carcinoma of the nasal cavity]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2000 Jun;14(6):269-70
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 19 cases adenoid cystic carcinoma of the nasal cavity].
  • OBJECTIVE: To study the biological features of adenoid cystic carcinoma of the nasal cavity in order to provide a basis for its clinical treatment.
  • METHOD: A retrospective analysis was made to 19 cases which were treated with operation combined with preoperative chemotherapy and radiation.
  • RESULT: 5, 8, and 10 years' follow-ups conducted post treatment showed the local recurrence rates were 5.3%, 21.1%, and 31.6% respectively.
  • CONCLUSION: Adenoid cystic carcinoma of the nasal cavity is highlighted because of high-degree local infiltration, the specific anatomy of the cavity, and the difficulty of wide-ranging surgical resection.
  • Preoperative chemotherapy combined with radiation has the advantages of extinguishing the recessive cancerous foci, inhibiting the primary foci and lowering local recurrences and cancerous metastases.
  • [MeSH-major] Carcinoma, Adenoid Cystic / therapy. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12541537.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Cavalot AL, Ricci E, Nazionale G, Palonta F, Fadda GL: Primary non-Hodgkin's lymphoma of the nasal cavity. Clinical case report and discussion. Acta Otolaryngol; 2000 Jun;120(4):545-50
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the nasal cavity. Clinical case report and discussion.
  • Primary non-Hodgkin's lymphoma of the nasal cavity is a disease more likely to affect men than women; it is characterized by a T cell immunophenotype and is often associated with involvement of the paranasal structures and with high recurrence rates.
  • Many authors report that its extremely poor prognosis depends on tumour stage and extension into the paranasal sinuses.
  • Patients with Ann Arbor stage IE limited to only one nasal cavity have better survival rates than those with the same stage but with tumour extension beyond the nasal cavity.
  • Patients with stages IIE, IIIE and IV have a very poor prognosis that does not seem to be affected by the use of conventional chemotherapy.
  • Optimal treatment for the disease is not yet known.
  • The use of radiotherapy alone has been reported in initial stages of the disease; however, given that its prognosis is burdened by frequent local or systemic recurrence or both, combined modality therapy has been applied in all stages.
  • In this case report we describe a case of primary non-Hodgkin's lymphoma of the nasal cavity localized at the middle turbinate, in combination with an updated literature review.
  • [MeSH-major] Hodgkin Disease. Nasal Cavity. Nose Neoplasms

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10958410.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] NORWAY
  •  go-up   go-down


14. Trabelsi A, Tebra S, Abdelkrim SB, Beizig N, Bdioui A, Hammedi F, Bouaouina N, Mokni M: Lymphoepithelial Carcinoma of the Nasal Cavity With EBV Infection in a North African Man. World J Oncol; 2010 Apr;1(2):91-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelial Carcinoma of the Nasal Cavity With EBV Infection in a North African Man.
  • We report the case of a 58-year-old Tunisian man who presented with a 2 months' history of left nasal obstruction and one episode of epistaxis.
  • Nasal endoscopy revealed a polypoid mass of the left nasal septum.
  • Magnetic resonance imaging showed a left nasal cavity tumor with erosion of the orbit.
  • Diagnosis of nasal cavity lymphoepithelial carcinoma EBV positive was performed on biopsy.
  • The patient was treated by chemotherapy and radiotherapy.
  • No tumor recurrence has been reported with a follow-up of 12 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):371-6 [11859210.001]
  • [Cites] Chin Med J (Engl). 2001 Feb;114(2):132-6 [11780191.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):424-32 [18755554.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):151-7 [17189068.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):401-6 [18164845.001]
  • (PMID = 29147186.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; EBV / Lymphoepithelial carcinoma / Nasal cavity / Pathology
  •  go-up   go-down


15. Hána V, Seidl Z, Vanĕcková M, Diblík P, Weiss V, Masopust V, Krsek M, Marek J: [Randomly discovered enlargement in the region of sella turcica]. Vnitr Lek; 2007 Jul-Aug;53(7-8):816-20
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computer tomography (CT) and magnetic resonance imaging (MRI) quite often detect unexpected cases of enlargement in the hypothalamus-hypophysial region, without the above methods being indicated for clinical manifested symptomatology provoked by the tumour.
  • X ray, CT or MRI are indicated in the case of head traumas, lateral nasal cavity inflammations, headaches, strokes, neurological diseases and other disorders.
  • Exact assessment of MRI results, of hormonal activity of the enlargement, of the relation to surrounding structures, especially the optic nerves, and the assessment of hypophysial functions are important for the therapeutic decision.
  • Depending on the type and extension of the tumour the options considered are pharmacotherapy (the treatment of choice in the case of prolactinomas), surgery, radiotherapy (today prevailingly using the gamma knife), and if no intervention is necessary, follow up with regular MRI examinations.
  • [MeSH-major] Pituitary Neoplasms / diagnosis. Sella Turcica
  • [MeSH-minor] Humans. Incidental Findings. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915425.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 7
  •  go-up   go-down


16. Unal A, Ozlugedik S, Tezer MS, Kulacoglu S, Ozcan M: An atypical esthesioneuroblastoma of the inferior nasal cavity and maxillary sinus: report of a case. Tumori; 2006 Sep-Oct;92(5):440-3
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An atypical esthesioneuroblastoma of the inferior nasal cavity and maxillary sinus: report of a case.
  • Esthesioneuroblastoma is a rare malignant tumor of the nasal cavity that originates from the olfactory epithelium.
  • In this paper a very rare clinical presentation of this tumor is described.
  • The tumor originated from the maxillary sinus and alveolar process, and was independent of the olfactory region.
  • The patient was a 14-year-old girl presenting with facial swelling and nasal obstruction.
  • Paranasal computed tomography showed a mass filling the right nasal cavity, infiltrating the alveolar process, eroding the anterior wall of the maxilla and invading the subcutaneous tissues of the cheek.
  • After neoadjuvant chemotherapy, we performed a right subtotal and left inferior maxillectomy and reconstructed the maxillary defect with a permanent obturator.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Maxillary Sinus Neoplasms. Nasal Cavity. Nose Neoplasms
  • [MeSH-minor] Adolescent. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168440.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


17. Strek P, Zagólski O, Składzień J, Przeklasa R, Blaschke J, Białas M, Urbanik A: [Olfactory neuroblastoma removed under endoscopic guidance]. Otolaryngol Pol; 2006;60(3):433-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Olfactory neuroblastoma is a rare tumour associated with high rates of recurrence and mortality.
  • Treatment includes surgery, radiotherapy, chemotherapy, or a combination.
  • The ideal treatment modality has yet to be determined.
  • During surgery, a 5 mm in diameter tumour was identified in the left superior nasal meatus.
  • On histopathological examination the diagnosis of esthesioneuroblastoma was established and confirmed by immunohistochemistry.
  • The tumour was classified according to Kadish as stage A, according to Biller as T1.
  • MR scans performed two months later disclosed pathological tissues in the left ethmoid region.
  • RESULTS: Multiple biopsies taken on subsequent frontosphenoethmoidectomy did not contain tumour cells.
  • CONCLUSIONS: The exclusively surgical treatment proved effective due to early stage of the tumour and no evidence of infiltration of the frontal skull base.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity / surgery. Nose Neoplasms / surgery
  • [MeSH-minor] Endoscopy. Ethmoid Sinusitis / etiology. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989461.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


18. Mori R, Sakai H, Kato M, Hida T, Nakajima M, Fukuda T, Fukunaga M, Abe T: [Olfactory neuroblastoma with spinal metastasis: case report]. No Shinkei Geka; 2007 May;35(5):503-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Olfactory neuroblastoma is a rare tumor of the nasal cavity.
  • It is a locally aggressive tumor with local recurrence, and distant metastasis occurs in 22-40% of patients.
  • Whole-spine irradiation of 32 Gy and lumber-spine irradiation of 10 Gy were performed.
  • Olfactory neuroblastoma is a radiosensitive tumor, and radiotherapy for spinal metastasis was reported to be effective.
  • However, effectiveness of chemotherapy was still uncertain.
  • Radiotherapy and further treatment including chemotherapy should be considered in case of spinal metastasis.
  • [MeSH-major] Cauda Equina. Esthesioneuroblastoma, Olfactory / secondary. Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity. Nose Neoplasms / pathology. Nose Neoplasms / surgery. Peripheral Nervous System Neoplasms / secondary

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491347.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Kim HJ, Cho HJ, Kim KS, Lee HS, Kim HJ, Jung E, Yoon JH: Results of salvage therapy after failure of initial treatment for advanced olfactory neuroblastoma. J Craniomaxillofac Surg; 2008 Jan;36(1):47-52
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of salvage therapy after failure of initial treatment for advanced olfactory neuroblastoma.
  • INTRODUCTION: Olfactory neuroblastoma is a very aggressive tumour with high rates of locoregional recurrence and distant metastasis.
  • Therefore, salvage therapy plays an important role in control of these neoplasms.
  • In this study, we present our experience and treatment outcomes for salvage therapy in patients with recurrent olfactory neuroblastoma.
  • Salvage therapy was performed in 6 of 8 patients with recurrence or metastasis and proved successful in 50% of them.
  • In the patients with locoregional recurrence, the success rate of salvage radiotherapy plus neck dissection was superior to salvage chemotherapy alone.
  • In addition, 17% of the patients with distant metastasis after initial treatment died after salvage therapy.
  • In 15% of patients with a clinical stage N0 at initial diagnosis, nodal recurrence developed and was successfully treated with salvage therapy.
  • CONCLUSION: Complete surgical resection, including craniofacial resection and postoperative radiotherapy without elective neck dissection, is the preferred approach in the treatment of advanced olfactory neuroblastoma.
  • In locoregional recurrence, successful salvage therapy may include selective neck dissection and radiotherapy, but in cases of distant metastasis, the prognosis was poor.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / secondary. Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity. Neoplasm Recurrence, Local / therapy. Nose Neoplasms / therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neck Dissection. Prognosis. Radiotherapy, High-Energy. Retrospective Studies

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312791.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


20. El Ghelbazouri N, Afifi Y, Benameur H, Bella A, Elhallaoui Y, Kettani F, Aït Ourhrouil M, Senouci K, Hassam B: [Oral verrucous carcinoma and human papillomavirus infection]. Ann Dermatol Venereol; 2007 Aug-Sep;134(8-9):659-62
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Verrucous carcinoma of the oral cavity is a clinical variant of squamous cell carcinoma.
  • PATIENTS AND METHODS: A 72 year-old woman with a history of actinic cheilitis consulted for a bulky tumour of the lips and palate.
  • Clinical examination revealed a highly infiltrated labial tumour vegetating and budding, with a thick edge.
  • A bulky tumour and firm masses were seen on the hard and soft palates.
  • The immunohistochemical study showed intestinal tumour containing HPV-16 virus.
  • The central facial scan showed involvement of the nasal fossae, soft palate and lips with lysis of the upper maxilla arcade and the osseous palate.
  • The patient died a few days before the start of preoperative chemotherapy following severe deterioration of her general state.
  • Diagnosis is based on histological examination.
  • Management and treatment are not codified but surgery remains the treatment of choice and relapse is common in the case of locoregional involvement.
  • [MeSH-minor] Aged. Fatal Outcome. Female. Humans. Lip Neoplasms / pathology. Maxillary Diseases / pathology. Neoplasm Invasiveness. Nose Neoplasms / pathology. Osteolysis / pathology. Palatal Neoplasms / pathology. Palate, Hard / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925690.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


21. Theilgaard SA, Buchwald C, Ingeholm P, Kornum Larsen S, Eriksen JG, Sand Hansen H: Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol; 2003 Apr;123(3):433-9
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: A retrospective review of all diagnosed cases of esthesioneuroblastoma registered in Denmark between 1978 and 2000 was carried out in order to obtain epidemiological data and optimize national treatment guidelines.
  • The histopathological findings were classified according to the grading system of Hyams The median follow-up time was 2.3 years (range 0.3-11.1 years).
  • A nationwide consensus regarding treatment was seen in patients classified as Kadish stages A and B.
  • CONCLUSIONS: The following therapeutic guidelines are suggested: Kadish stage A patients, surgical tumour resection and radiotherapy; Kadish stage B, surgical tumour resection and radiotherapy; Kadish stage C, surgical tumour resection via a craniofacial resection and radiotherapy combined with chemotherapy.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / epidemiology. Nasal Cavity. Nose Neoplasms / epidemiology. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy / adverse effects. Denmark / epidemiology. Disease-Free Survival. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Postoperative Complications / epidemiology. Registries. Retrospective Studies. Smoking / epidemiology. Survival Rate

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12737303.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


22. Rischin D, Porceddu S, Peters L, Martin J, Corry J, Weih L: Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. Head Neck; 2004 May;26(5):435-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The optimal treatment approach for SNUC has not been established was performed.
  • One patient with a T1N0 nasal cavity tumor treated with radiation alone has not relapsed.
  • CONCLUSION: Induction chemotherapy followed by concurrent chemoradiation is promising treatment strategy for SNUC.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / radiotherapy. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Probability. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc. Head Neck 26: 435-441, 2004.
  • (PMID = 15122660.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Iseh KR, Aliyu D: Surgical considerations in the management of tumours of the nose and paranasal sinuses in a Northern Nigerian Teaching Hospital. West Afr J Med; 2009 Nov-Dec;28(6):371-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 46(83.6%) patients the tumours had extended beyond the nasal cavity or one sinus cavity to contiguous structures.
  • These malignant cases needed radiotherapy and chemotherapy.
  • CONCLUSION: Majority of the cases were characterised by late presentation, requiring surgical approaches such as lateral rhinotomy, total maxillectomy or craniofacial resection depending on the extent of the tumour.
  • Provision of free medical care and modern facilities for early diagnosis, treatment, and health education are needed to reverse the trend.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Hospitals, Teaching. Humans. Male. Middle Aged. Neoplasm Staging. Nigeria / epidemiology. Otorhinolaryngologic Surgical Procedures / methods. Sex Distribution. Socioeconomic Factors. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486095.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


24. Oskouian RJ Jr, Jane JA Sr, Dumont AS, Sheehan JM, Laurent JJ, Levine PA: Esthesioneuroblastoma: clinical presentation, radiological, and pathological features, treatment, review of the literature, and the University of Virginia experience. Neurosurg Focus; 2002 May 15;12(5):e4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma: clinical presentation, radiological, and pathological features, treatment, review of the literature, and the University of Virginia experience.
  • Esthesioneuroblastoma is a rare and malignant upper nasal cavity neoplasm involving the anterior skull base.
  • Treatment includes surgery, radiotherapy, chemotherapy, or a combination.
  • The ideal treatment modality has yet to be determined.
  • Management strategies for this neoplasm lack uniformity, and there is no universally accepted staging system.
  • In this paper the authors discuss the clinical presentation, radiological and pathological features, and treatment of this rare, malignant skull base neoplasm, as well as review the literature.
  • They also present their results and treatment regimen, which includes preoperative radio- and chemotherapy or 1) craniofacial resection if the lesion has a significant intracerebral component, or 2) frontal sinus resection if little intracranial extension exists.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Nasal Cavity. Nose Neoplasms
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Postoperative Complications. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119902.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 71
  •  go-up   go-down


25. Windfuhr JP: Primitive neuroectodermal tumor of the head and neck: incidence, diagnosis, and management. Ann Otol Rhinol Laryngol; 2004 Jul;113(7):533-43
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumor of the head and neck: incidence, diagnosis, and management.
  • Because of their rare occurrence, optimal therapy is challenging, particularly if they occur in the head and neck.
  • Diagnosis is based on history, immunostaining with at least 2 neural markers, ultrastructural examination, and evidence of an abnormal t(11;22)(q24;q12) translocation as the hallmark for the Ewing's sarcoma family.
  • The prognosis in general is poor because of overt metastasis at the time of diagnosis.
  • Most patients presented with a tumor in the nasal cavity, paranasal sinuses, or neck.
  • Symptoms developed rapidly (3.6 months, on average), and a lethal outcome occurred in 9 patients.
  • This highly malignant tumor requires an aggressive combination of radical resection, chemotherapy, and radiotherapy.
  • [MeSH-major] Brain Neoplasms / diagnosis. Head and Neck Neoplasms. Neuroectodermal Tumors, Primitive. Sarcoma, Ewing / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain / diagnostic imaging. Brain / pathology. Brain / surgery. Child. Chromosomes, Human, Pair 11 / genetics. Combined Modality Therapy. Diagnosis, Differential. Humans. Immunohistochemistry. Incidence. Magnetic Resonance Imaging. Male. Neurosurgical Procedures / methods. Tomography, X-Ray Computed. Translocation, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15274413.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


26. Sakamoto E, Yamane T, Nakane T, Takeoka Y, Hirose A, Hagihara K, Nakamae H, Ohta K, Hirayama M, Ikura Y, Ohsawa M, Sawada T, Kitoh T, Hino M: [Temporary effective treatment with L-asparaginase for a patient with refractory nasal NK/T-cell lymphoma]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1993-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Temporary effective treatment with L-asparaginase for a patient with refractory nasal NK/T-cell lymphoma].
  • A 48-year-old man was referred to Sakai Municipal Hospital with nasal discharge and right facial swelling.
  • The pathological findings of a nasal cavity tumor revealed stage IIB NK/T-cell lymphoma.
  • He was admitted to our hospital and received CHOP therapy, resulting in progressive disease.
  • Irradiation therapy combined with DeVIC chemotherapy also could not shrink his lymphoma.
  • Then, two courses of L-asparaginase(L-Asp) were administered, resulting in partial improvement of the nasal and pharynx lesions, resolution of the fever and improvement of his performance status.
  • On the day before a third course of L-Asp, he again developed a lowgrade fever.
  • Although L-Asp was effective against nasal NK/T-cell lymphoma resistant to combination chemotherapy and irradiation therapy, the effectiveness of the single agent with L-Asp was only transient.
  • L-Asp based regimen should be used as first-line therapy if asparagine synthetase protein expression is low using an immunohistochemical method.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Asparaginase / therapeutic use. Lymphoma, T-Cell / drug therapy. Nose Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Drug Administration Schedule. Fatal Outcome. Humans. Kidney Neoplasms / pathology. Liver Neoplasms / pathology. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282743.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


27. Constantinidis J, Steinhart H, Koch M, Buchfelder M, Schaenzer A, Weidenbecher M, Iro H: Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975-2000. Otolaryngol Head Neck Surg; 2004 May;130(5):567-74
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Olfactory neuroblastoma constitutes a rare and, in clinical terms, biologically variable tumor of the nasal cavity, paranasal sinuses, and the base of the skull and presents a challenge to a modern multidisciplinary therapy.
  • Generally acknowledged prognostic factors and a standard therapy fail to exist.
  • Surgical therapy was performed on 23 patients (88.5%), surgery being the exclusive form of therapy (monotherapy) in 5 of these patients.
  • Combined therapy was carried out in 18 cases (surgery, radiotherapy, chemotherapy).
  • Seven (26.9%) of the overall group of treated patients developed a recurrence.
  • Salvage therapy was successful in 60% (3 of 5 patients).
  • Fifteen-year survival following salvage therapy amounts to 60%.
  • CONCLUSIONS: The therapy of olfactory neuroblastoma calls for an interdisciplinary multimodal therapeutic strategy, particularly in the case of advanced tumors.
  • Tumor staging and histopathologic grading according to Hyams are important factors for survival and prognosis.
  • Aggressive salvage therapy can lead to a distinct improvement of long-term survival.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / pathology. Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity / pathology. Nose Neoplasms / pathology. Nose Neoplasms / therapy

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15138422.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Rhee KH, Hong SC, An JM, Huh J, Sook RJ, Lee JS, Suh C: Mediastinal single nodal relapse of a nasal NK/T cell lymphoma. Korean J Intern Med; 2007 Sep;22(3):201-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal single nodal relapse of a nasal NK/T cell lymphoma.
  • A nasal NK/T cell lymphoma is a very aggressive form of lymphoma.
  • Patterns of relapse after treatment have not been systematically evaluated, and mediastinal nodal relapse at a primary site has never been documented.
  • We describe here a 40-year old man who presented with a nasal obstruction caused by a protruding mass that was identified as a nasal NK/T cell lymphoma.
  • The initial work-up, including chest and abdominopelvic computed tomography (CT) and positron emission tomography (PET), showed no regional or distant metastasis.
  • A CT scan performed following three cycles of chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) showed that the mass had nearly disappeared.
  • Radiation therapy undertaken following chemotherapy was given to the primary site.
  • However, PET performed following radiotherapy revealed a single mediastinal lymphadenopathy, with no evidence of residual tumor in the nasal cavity.
  • A biopsy using video-assisted thoracoscopy (VATS) showed the presence of a recurrent NK/T cell lymphoma with an immunophenotype identical to that of the primary nasal lymphoma.
  • An additional three cycles of CHOP chemotherapy were administered, and the patient remains alive, with no evidence of disease 30 months after the initial relapse.
  • These findings indicate that early detection with PET and prompt surgical excision with the use of VATS can lead to successful treatment of a relapsed nasal NK/T cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Lymphatic Metastasis. Male. Positron-Emission Tomography. Prednisolone / administration & dosage. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jan;18(1):54-63 [10623693.001]
  • [Cites] Ai Zheng. 2006 Apr;25(4):465-70 [16613682.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1091-7 [12173024.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1197-202 [14654477.001]
  • [Cites] Acta Cytol. 2003 Nov-Dec;47(6):1063-8 [14674081.001]
  • [Cites] Blood. 2004 Jan 1;103(1):216-21 [12933580.001]
  • [Cites] Histopathology. 2004 May;44(5):480-9 [15139996.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):940-6 [3373265.001]
  • [Cites] J Clin Oncol. 1988 Dec;6(12):1832-7 [3199167.001]
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):268-79 [1996731.001]
  • [Cites] Acta Oncol. 1993;32(1):69-72 [8466767.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):666-70 [7884427.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):70-7 [9440725.001]
  • [Cites] Jpn J Clin Oncol. 2005 Jan;35(1):1-5 [15681596.001]
  • [Cites] Nucl Med Commun. 2005 Nov;26(11):989-94 [16208177.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):181-9 [16382127.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):612-8 [16380410.001]
  • [Cites] AJR Am J Roentgenol. 2000 Apr;174(4):1141-5 [10749267.001]
  • (PMID = 17939339.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Other-IDs] NLM/ PMC2687701
  •  go-up   go-down


29. Cappabianca P, Esposito F, Esposito I, Cavallo LM, Leone CA: Use of a thrombin-gelatin haemostatic matrix in endoscopic endonasal extended approaches: technical note. Acta Neurochir (Wien); 2009 Jan;151(1):69-77; discussion 77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed the patients' operative records to determine the source, type of bleeding and haemostatic strategy.
  • RESULTS: We analysed bleedings from the venous sinuses, arteries, tumour bed and internal carotid artery and observed complete haemostasis immediately after application of FloSeal.
  • [MeSH-major] Endoscopy / methods. Gelatin Sponge, Absorbable / therapeutic use. Hemostasis, Surgical / methods. Nasal Cavity / surgery. Neurosurgical Procedures / methods. Postoperative Hemorrhage / drug therapy
  • [MeSH-minor] Adenoma / pathology. Adenoma / surgery. Adult. Aged. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Craniopharyngioma / pathology. Craniopharyngioma / surgery. Female. Humans. Intraoperative Complications / drug therapy. Intraoperative Complications / etiology. Intraoperative Complications / prevention & control. Male. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Middle Aged. Pituitary Neoplasms / pathology. Pituitary Neoplasms / surgery. Skull Base Neoplasms / pathology. Skull Base Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19129962.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / FloSeal Matrix
  •  go-up   go-down


30. Fraioli MF, Moschettoni L, Catena E, Fraioli C: Cystic craniopharyngioma: trans-sphenoidal surgery and intra-cystic apposition of "bleomycin wax". Acta Neurochir (Wien); 2010 Feb;152(2):293-6
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The current therapeutic approach to craniopharyngioma is multidisciplinary.
  • Sub-total removal, followed by adjuvant treatments, especially in large cystic tumours, is an accepted regime reported by many authors.
  • There was no evidence of tumour recurrence after a follow-up period of 5.4 years.
  • [MeSH-major] Bleomycin / administration & dosage. Craniopharyngioma / drug therapy. Craniopharyngioma / surgery. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / surgery. Sphenoid Bone / surgery
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Child. Cysts / drug therapy. Cysts / pathology. Diabetes Insipidus / drug therapy. Diabetes Insipidus / etiology. Drug Combinations. Epithelial Cells / pathology. Humans. Magnetic Resonance Imaging. Male. Nasal Cavity / anatomy & histology. Nasal Cavity / surgery. Neurosurgical Procedures. Optic Chiasm / pathology. Optic Chiasm / surgery. Palmitates / administration & dosage. Pituitary Gland / pathology. Pituitary Gland / surgery. Postoperative Complications / drug therapy. Postoperative Complications / etiology. Sella Turcica / pathology. Sella Turcica / surgery. Treatment Outcome. Waxes

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19390776.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Drug Combinations; 0 / Palmitates; 0 / Waxes; 11056-06-7 / Bleomycin; 8021-48-5 / bone wax
  •  go-up   go-down






Advertisement